NIAID supports efforts to improve the seasonal flu vaccines which are already available to the public.

Thursday, August 8, 2019 NIH-Funded Study Will Test Seasonal Flu Vaccines With Two Experimental Adjuvants In addition to developing new, more effective influenza vaccines, NIAID supports efforts to improve the seasonal flu vaccines already available. In a new Phase 1 trial taking place at NIAID-funded sites across the United States, researchers will test the safety and immune response of two established seasonal influenza vaccines, Fluzone and Flublok (both manufactured by Sanofi Pasteur, the vaccines global business unit of Sanofi), when given on their own, or with one of two novel adjuvants. These adjuvants, AF03 (manufactured by Sanofi Pasteur) and Advax-CpG55.2™ (manufactured by Vaxine Pty Ltd) are designed to boost recipients' immune responses to the vaccines. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107